07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Enfortumab vedotin: Phase I data

An open-label, dose-escalation, North American Phase I trial in 28 evaluable patients with metastatic urothelial cancer previously treated with >=1 chemotherapy regimen or who were unfit for cisplatin showed that once-weekly 0.5, 0.75, 1 and...
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Seattle Genetics, Abbott, Astellas, Pfizer deal

Seattle Genetics disclosed in its 4Q11 earnings that it received undisclosed milestone payments from Abbott and Pfizer under separate 2011 deals granting the pharmas rights to use Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Company News

Seattle Genetics, Astellas deal

Seattle Genetics exercised a 2007 option from Astellas' Agensys Inc. subsidiary to co-develop and co-commercialize ASG-22ME . Agensys submitted an IND last quarter for a Phase I trial of the antibody-drug conjugate (ADC) targeting nectin-4...